Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia

Alan Zanardi, Antonio Conti, Marco Cremonesi, Patrizia D'Adamo, Enrica Gilberti, Pietro Apostoli, Carlo Vittorio Cannistraci, Alberto Piperno, Samuel David, Massimo Alessio

Research output: Contribution to journalArticle

Abstract

Aceruloplasminemia is a monogenic disease caused by mutations in the ceruloplasmin gene that result in loss of protein ferroxidase activity. Ceruloplasmin plays a role in iron homeostasis, and its activity impairment leads to iron accumulation in liver, pancreas, and brain. Iron deposition promotes diabetes, retinal degeneration, and progressive neurodegeneration. Current therapies mainly based on iron chelation, partially control systemic iron deposition but are ineffective on neurodegeneration. We investigated the potential of ceruloplasmin replacement therapy in reducing the neurological pathology in the ceruloplasmin-knockout (CpKO) mouse model of aceruloplasminemia. CpKO mice were intraperitoneal administered for 2 months with human ceruloplasmin that was able to enter the brain inducing replacement of the protein levels and rescue of ferroxidase activity. Ceruloplasmin-treated mice showed amelioration of motor incoordination that was associated with diminished loss of Purkinje neurons and reduced brain iron deposition, in particular in the choroid plexus. Computational analysis showed that ceruloplasmin-treated CpKO mice share a similar pattern with wild-type animals, highlighting the efficacy of the therapy. These data suggest that enzyme replacement therapy may be a promising strategy for the treatment of aceruloplasminemia.

Original languageEnglish
Pages (from-to)91-106
Number of pages16
JournalEMBO Molecular Medicine
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 2018

Fingerprint

Ceruloplasmin
Iron
Knockout Mice
Therapeutics
Brain
Enzyme Replacement Therapy
Retinal Degeneration
Choroid Plexus
Wild Animals
Purkinje Cells
Ataxia
Pancreas
Proteins
Homeostasis
Pathology

Keywords

  • Journal Article

Cite this

Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia. / Zanardi, Alan; Conti, Antonio; Cremonesi, Marco; D'Adamo, Patrizia; Gilberti, Enrica; Apostoli, Pietro; Cannistraci, Carlo Vittorio; Piperno, Alberto; David, Samuel; Alessio, Massimo.

In: EMBO Molecular Medicine, Vol. 10, No. 1, 01.2018, p. 91-106.

Research output: Contribution to journalArticle

Zanardi, A, Conti, A, Cremonesi, M, D'Adamo, P, Gilberti, E, Apostoli, P, Cannistraci, CV, Piperno, A, David, S & Alessio, M 2018, 'Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia', EMBO Molecular Medicine, vol. 10, no. 1, pp. 91-106. https://doi.org/10.15252/emmm.201708361
Zanardi, Alan ; Conti, Antonio ; Cremonesi, Marco ; D'Adamo, Patrizia ; Gilberti, Enrica ; Apostoli, Pietro ; Cannistraci, Carlo Vittorio ; Piperno, Alberto ; David, Samuel ; Alessio, Massimo. / Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia. In: EMBO Molecular Medicine. 2018 ; Vol. 10, No. 1. pp. 91-106.
@article{edacf50acbf94005aa4ebbe23ae1b092,
title = "Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia",
abstract = "Aceruloplasminemia is a monogenic disease caused by mutations in the ceruloplasmin gene that result in loss of protein ferroxidase activity. Ceruloplasmin plays a role in iron homeostasis, and its activity impairment leads to iron accumulation in liver, pancreas, and brain. Iron deposition promotes diabetes, retinal degeneration, and progressive neurodegeneration. Current therapies mainly based on iron chelation, partially control systemic iron deposition but are ineffective on neurodegeneration. We investigated the potential of ceruloplasmin replacement therapy in reducing the neurological pathology in the ceruloplasmin-knockout (CpKO) mouse model of aceruloplasminemia. CpKO mice were intraperitoneal administered for 2 months with human ceruloplasmin that was able to enter the brain inducing replacement of the protein levels and rescue of ferroxidase activity. Ceruloplasmin-treated mice showed amelioration of motor incoordination that was associated with diminished loss of Purkinje neurons and reduced brain iron deposition, in particular in the choroid plexus. Computational analysis showed that ceruloplasmin-treated CpKO mice share a similar pattern with wild-type animals, highlighting the efficacy of the therapy. These data suggest that enzyme replacement therapy may be a promising strategy for the treatment of aceruloplasminemia.",
keywords = "Journal Article",
author = "Alan Zanardi and Antonio Conti and Marco Cremonesi and Patrizia D'Adamo and Enrica Gilberti and Pietro Apostoli and Cannistraci, {Carlo Vittorio} and Alberto Piperno and Samuel David and Massimo Alessio",
note = "{\circledC} 2017 The Authors. Published under the terms of the CC BY 4.0 license.",
year = "2018",
month = "1",
doi = "10.15252/emmm.201708361",
language = "English",
volume = "10",
pages = "91--106",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia

AU - Zanardi, Alan

AU - Conti, Antonio

AU - Cremonesi, Marco

AU - D'Adamo, Patrizia

AU - Gilberti, Enrica

AU - Apostoli, Pietro

AU - Cannistraci, Carlo Vittorio

AU - Piperno, Alberto

AU - David, Samuel

AU - Alessio, Massimo

N1 - © 2017 The Authors. Published under the terms of the CC BY 4.0 license.

PY - 2018/1

Y1 - 2018/1

N2 - Aceruloplasminemia is a monogenic disease caused by mutations in the ceruloplasmin gene that result in loss of protein ferroxidase activity. Ceruloplasmin plays a role in iron homeostasis, and its activity impairment leads to iron accumulation in liver, pancreas, and brain. Iron deposition promotes diabetes, retinal degeneration, and progressive neurodegeneration. Current therapies mainly based on iron chelation, partially control systemic iron deposition but are ineffective on neurodegeneration. We investigated the potential of ceruloplasmin replacement therapy in reducing the neurological pathology in the ceruloplasmin-knockout (CpKO) mouse model of aceruloplasminemia. CpKO mice were intraperitoneal administered for 2 months with human ceruloplasmin that was able to enter the brain inducing replacement of the protein levels and rescue of ferroxidase activity. Ceruloplasmin-treated mice showed amelioration of motor incoordination that was associated with diminished loss of Purkinje neurons and reduced brain iron deposition, in particular in the choroid plexus. Computational analysis showed that ceruloplasmin-treated CpKO mice share a similar pattern with wild-type animals, highlighting the efficacy of the therapy. These data suggest that enzyme replacement therapy may be a promising strategy for the treatment of aceruloplasminemia.

AB - Aceruloplasminemia is a monogenic disease caused by mutations in the ceruloplasmin gene that result in loss of protein ferroxidase activity. Ceruloplasmin plays a role in iron homeostasis, and its activity impairment leads to iron accumulation in liver, pancreas, and brain. Iron deposition promotes diabetes, retinal degeneration, and progressive neurodegeneration. Current therapies mainly based on iron chelation, partially control systemic iron deposition but are ineffective on neurodegeneration. We investigated the potential of ceruloplasmin replacement therapy in reducing the neurological pathology in the ceruloplasmin-knockout (CpKO) mouse model of aceruloplasminemia. CpKO mice were intraperitoneal administered for 2 months with human ceruloplasmin that was able to enter the brain inducing replacement of the protein levels and rescue of ferroxidase activity. Ceruloplasmin-treated mice showed amelioration of motor incoordination that was associated with diminished loss of Purkinje neurons and reduced brain iron deposition, in particular in the choroid plexus. Computational analysis showed that ceruloplasmin-treated CpKO mice share a similar pattern with wild-type animals, highlighting the efficacy of the therapy. These data suggest that enzyme replacement therapy may be a promising strategy for the treatment of aceruloplasminemia.

KW - Journal Article

U2 - 10.15252/emmm.201708361

DO - 10.15252/emmm.201708361

M3 - Article

C2 - 29183916

VL - 10

SP - 91

EP - 106

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 1

ER -